Loading…
Arbutus Biopharma Corporation is projected to rise to $5.48 by 2027, a +18% move from its current price of $4.64. ABUS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.54 | $4.64 | $4.74 | -0.03% |
| May 30 | $4.50 | $4.64 | $4.78 | -0.06% |
| May 31 | $4.47 | $4.64 | $4.81 | -0.09% |
| Jun 1 | $4.44 | $4.63 | $4.84 | -0.12% |
| Jun 2 | $4.42 | $4.63 | $4.86 | -0.15% |
| Jun 3 | $4.39 | $4.63 | $4.88 | -0.18% |
| Jun 4 | $4.37 | $4.63 | $4.90 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.37 | $4.63 | $4.90 | -0.22% |
| Week 2 | $4.26 | $4.62 | $5.01 | -0.43% |
| Week 3 | $4.18 | $4.61 | $5.09 | -0.65% |
| Week 4 | $4.10 | $4.60 | $5.16 | -0.86% |
| Week 5 | $4.04 | $4.59 | $5.21 | -1.07% |
| Week 6 | $3.98 | $4.58 | $5.27 | -1.29% |
| Week 7 | $3.93 | $4.57 | $5.31 | -1.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious disease in the United States.
Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation (ABUS) is currently priced at $4.35 and has a market capitalization of $859.29M. It is ranked 2642 in the market.
The stock’s near-term technical picture shows the price trading around its key moving averages, with SMA50 at $4.36 and SMA200 at $4.33.
Its 30-day price range spans $3.85 to $4.92, and annualized volatility sits at 40.
The multi-year forecast paints a path of upside, with the average price forecast rising from $4.35 in 2026 to $8.12 in 2030, then to $17.17 in 2040 and $36.63 in 2050, with max values up to $59.94 by 2050.
A major floor 20.9% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 9.6% above — clearing it would confirm fresh momentum.
Key ABUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.49 | Buy | $4.51 | Buy |
| MA 10 | $4.37 | Buy | $4.43 | Buy |
| MA 20 | $4.35 | Buy | $4.39 | Buy |
| MA 50 | $4.37 | Buy | $4.38 | Buy |
| MA 100 | $4.37 | Buy | $4.36 | Buy |
| MA 200 | $4.35 | Buy | $4.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.81 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 213.45 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 6.91 | Buy |
| Bollinger %B (20,2) | 1.07 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | 0.12 | Buy |
| Ultimate (7,14,28) | 68.65 | Neutral |
| Momentum (10) | 0.33 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 4.61 | Buy |
| ADX (14) | 9.98 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bullish, with RSI14 at 50.
Near-term price dynamics show the stock trading close to its moving averages, with SMA50 at $4.36 and SMA200 at $4.33 as reference levels.
Key support is seen at $4.13 and resistance at $4.72, while the 30-day range runs from $3.85 to $4.92.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.67 | $4.64 | $5.91 | 0% | Neutral | |
| $4.44 | $5.48 | $7.12 | +18% | Neutral | |
| $4.68 | $5.90 | $7.89 | +27% | Bullish | |
| $5.81 | $7.46 | $10.21 | +61% | Bullish | |
| $6.94 | $9.05 | $12.63 | +95% | Bullish | |
| $7.10 | $9.39 | $13.33 | +102% | Bullish | |
| $7.70 | $10.31 | $14.87 | +122% | Bullish | |
| $8.03 | $10.89 | $15.93 | +135% | Bullish | |
| $8.54 | $11.71 | $17.36 | +152% | Bullish | |
| $10.79 | $14.96 | $22.44 | +222% | Bullish | |
| $13.74 | $20.01 | $31.60 | +331% | Bullish | |
| $27.24 | $43.12 | $73.49 | +829% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.67 | $4.64 | $5.45 | +0.00% |
| June 2026 | $3.96 | $4.62 | $5.52 | -0.35% |
| July 2026 | $3.83 | $4.51 | $5.44 | -2.44% |
| August 2026 | $3.85 | $4.55 | $5.54 | +0.93% |
| September 2026 | $3.90 | $4.63 | $5.67 | +1.63% |
| October 2026 | $3.83 | $4.57 | $5.63 | -1.20% |
| November 2026 | $3.83 | $4.58 | $5.67 | +0.21% |
| December 2026 | $3.96 | $4.75 | $5.91 | +3.70% |
Click any year to see its month-by-month ABUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ABUS is projected to trade between $3.67 and $5.91, averaging $4.64 — a potential gain of 0% from today's $4.64. Price action looks broadly range-bound.
Arbutus Biopharma Corporation's 2027 outlook centres on $5.48, within a $4.44 to $7.12 range. That is up +18% on the projected 2026 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ABUS could reach as high as $7.89, with a base case around $5.90 and support toward $4.68 — roughly +27% from $4.64. Momentum favours further upside here.
Expect ABUS to range from $5.81 to $10.21 through 2029. The $7.46 average target implies a +61% move from current prices. That is up +26% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ABUS price prediction for 2030 points to an average of $9.05 (low $6.94, high $12.63) — a potential gain of +95% on today's $4.64. Momentum favours further upside here.
In 2031, ABUS is projected to trade between $7.10 and $13.33, averaging $9.39 — a potential gain of +102% from today's $4.64. That is up +4% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Arbutus Biopharma Corporation's 2032 outlook centres on $10.31, within a $7.70 to $14.87 range. That is up +10% on the projected 2031 average. That marks a +122% change versus current levels. Momentum favours further upside here.
By 2033, ABUS could reach as high as $15.93, with a base case around $10.89 and support toward $8.03 — roughly +135% from $4.64. Buyers look set to stay in control over this stretch.
Expect ABUS to range from $8.54 to $17.36 through 2034. The $11.71 average target implies a +152% move from current prices. That is up +8% on the projected 2033 average. Momentum favours further upside here.
The ABUS price prediction for 2035 points to an average of $14.96 (low $10.79, high $22.44) — a potential gain of +222% on today's $4.64. Buyers look set to stay in control over this stretch.
In 2040, ABUS is projected to trade between $13.74 and $31.60, averaging $20.01 — a potential gain of +331% from today's $4.64. That is up +34% on the projected 2035 average. Momentum favours further upside here.
Arbutus Biopharma Corporation's 2050 outlook centres on $43.12, within a $27.24 to $73.49 range. That is up +115% on the projected 2040 average. That marks a +829% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABUS today (≈ 215.517241 ABUS) could be worth
$9,292.63
+$8,292.63 (+829%) by 2050 · US Dollar
Based on the average projected ABUS price of $43.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABUSwould be worth at today's price.
$1,000 invested in ABUS on May 27, 2025 (≈ 289.855068 ABUS) would be worth
$1,344.93
+$344.93 (+34.5%) today · 1.34× · US Dollar
Based on a ABUS entry price of $3.45 vs. today's $4.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.37 | $1,061.78 | +6.2% |
| 1 month ago | $4.28 | $1,084.11 | +8.4% |
| 3 months ago | $4.7 | $987.23 | -1.3% |
| 6 months ago | $4.41 | $1,052.15 | +5.2% |
| 1 year ago | $3.45 | $1,344.93 | +34.5% |
| All time (5.0y) ago | $2.86 | $1,622.38 | +62.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABUS forecast.
Our base-case forecast reaches $9.30 around 2031.
Implied market cap at $9.30: $1.84B
The multi-year forecast depicts a bullish trajectory across the late-2020s into the 2030s and beyond. By 2030, the avg price is forecast at $8.12 with a ROI of 86.7 and a bullish sentiment; by 2040, the avg price is forecast at $17.17 with a ROI of 294.6 and a bullish sentiment; by 2050, the avg price is forecast at $36.63 with a ROI of 742 and a bullish sentiment.
These are estimates and not guarantees. They reflect potential upside as the company advances its HBV programs described in the pipeline and engages in continued development and commercialization efforts, subject to clinical and regulatory outcomes.
Tap a question to reveal the answer.
2030 min $6.33, avg $8.12, max $11.09; ROI 86.7; sentiment BULLISH.
Forecasts show bullish sentiment in 2030–2050 with average prices rising to $8.12 (2030), $17.17 (2040), and $36.63 (2050) and ROIs of 86.7, 294.6, and 742 respectively; these are estimates, not guarantees.
Yes. The max values show ABUS could exceed $15, with a max of $19.03 in 2035 and higher later (e.g., $26.22 in 2040 and $59.94 in 2050).
Current price is $4.35 and market cap is $859.29M.
The 30-day range is $3.85 to $4.92, RSI14 is 50.
Arbutus Biopharma Corporation Community Discussion
0Share your Arbutus Biopharma Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.